Importantly, reports of increased IL-17 (or IL-17F) are stronger in acute/severe COVID-19 and in analyses linking endothelial activation to persistent symptoms; nonetheless, causality for chronic pulmonary symptoms remains under study [123,124]. The gene discussed is IL17A; the disease is COVID-19.